Spontaneous Atrio Ventricular Conduction Preservation
Launched by LIVANOVA · Apr 3, 2008
Trial Information
Current as of May 06, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patient has been primo-implanted with a Symphony™ 2550 or 2450 devices for less than 3 months
- • Patient with a normal spontaneous AV conduction at rest (PR \< 250 ms)
- • Patient implanted for Sinus Node Dysfunction, Braycardia-Tachycardia Syndrome, carotid sinus syndrome/ vaso vagal syndrome or paroxistic AV Block
- • Patient implanted with a bipolar right-atrial lead and ventricular lead available in the local market
- • Patient has signed a consent form after having received the appropriate information
- Exclusion Criteria:
- • Permanent 1st, 2nd or 3rd AV block
- • Patient having a medical status complying with one of the following cases
- • patient suffering from sustained ventricular arrhythmias
- • patient having sustained a myocardial infarction within the last month
- • patient having undergone cardiac surgery within the last month
- • patient suffering from severe aortic stenosis
- • patient suffering from unstable angina pectoris
- • patient presents with permanent atrial arrhythmias
- • Patient is not able to understand the study objectives and protocol or refuses to co-operate
- • Patient is not available for scheduled follow-up
- • Patient has a life expectancy less than one year
- • Patient is included into another clinical study
- • Patient is minor or a pregnant woman
About Livanova
Livanova is a global medical technology company specializing in innovative solutions for the treatment of neurological and cardiovascular diseases. With a commitment to advancing patient care, Livanova develops cutting-edge devices and therapies that enhance the quality of life for individuals suffering from complex medical conditions. The company focuses on research and development, collaborating with healthcare professionals and institutions to conduct clinical trials that validate the safety and efficacy of its products. Livanova's dedication to innovation is driven by a passion for transforming healthcare through technology, ultimately aiming to improve outcomes for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Leeds, , United Kingdom
Nantes, , France
Besancon, , France
Birmingham, , United Kingdom
Lübeck, , Germany
Bristol, , United Kingdom
Aalst, , Belgium
Hull, , United Kingdom
Rennes, , France
Albi, , France
Angers, , France
Grenoble, , France
Paris Cedex 16, , France
Rouen, , France
Vandoeuvre Les Nancy, , France
Munchen, , Germany
Baudour, , Belgium
Bruxelles, , Belgium
Campus St. Elisabeth Uccle, , Belgium
Moen, , Belgium
Montigny Le Tilleul, , Belgium
Tivoli, , Belgium
Aix En Provence, , France
Castres Mazamet, , France
Clermont Ferrand, , France
Lille, , France
Limoges, , France
Montpellier, , France
Mulhouse, , France
Nantes, , France
Nice, , France
St Cloud, , France
Bonn, , Germany
Bonn, , Germany
Bremen, , Germany
Halberstadt, , Germany
Holzminden, , Germany
Hürth, , Germany
Kassel, , Germany
Koln, , Germany
Luedenscheid, , Germany
Lüneburg, , Germany
Mainz, , Germany
Marburg, , Germany
Memmingen, , Germany
Munchen, , Germany
Munchen, , Germany
Peine, , Germany
Regensburg, , Germany
Starnberg, , Germany
Ulm, , Germany
Waren, , Germany
Wolgast, , Germany
Avellino, , Italy
Chiari (Bs), , Italy
Conegliano (Tv), , Italy
Foligno (Pg), , Italy
Mestre (Ve), , Italy
Portogruaro (Ve), , Italy
San Donato, , Italy
Sesto S. Giovanni (Mi), , Italy
Trento, , Italy
Venezia, , Italy
Voghera, , Italy
Burton On Trent, , United Kingdom
London, , United Kingdom
London, , United Kingdom
Patients applied
Trial Officials
Jean Marc DAVY, PhD
Principal Investigator
CH Montpellier
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials